Nevertheless, PD-1 inhibitors obtained poor objective response rates (15-20%) in phase I/II trials and failed to meet the primary end points in phase III trials for patients with HCC, which was primarily attributable to ICB resistance induced by the immunosuppressive TME, as well as to drug discontinuation caused by serious immune-related adverse events. Here, PDCD1 is linked to hepatocellular carcinoma.